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Abstract
Background: The early identification of patients at risk of dying from community-acquired pneumonia (CAP)
is critical for their treatment and for defining hospital resource consumption. Mid-regional pro-adrenomedullin
(MR-proADM) has been extensively investigated for its prognostic value in CAP. However, the results are conflicting.
The purpose of the present meta-analysis was to explore the diagnostic accuracy of MR-proADM for predicting
mortality in patients suffering from CAP, particularly emergency department (ED) patients.
Method: We systematically searched the PubMed, Embase, Web of Knowledge and Cochrane databases. Studies were
included if a 2 × 2 contingency table could be constructed based on both the MR-proADM level and the complications
or mortality of patients diagnosed with CAP. The prognostic accuracy of MR-proADM in CAP was assessed using the
bivariate meta-analysis model. We used the Q-test and I2 index to evaluate heterogeneity.
Results: MR-proADM displayed moderate diagnostic accuracy for predicting complications in CAP, with an overall area
under the SROC curve (AUC) of 0.74 (95 % CI: 0.70–0.78). Eight studies with a total of 4119 patients in the emergency
department (ED) were included. An elevated MR-proADM level was associated with increased risk of death from CAP
(RR 6.16, 95 % CI 4.71–8.06); the I2 value was 0.0 %, and a fixed-effects model was used to pool RR. The pooled
sensitivity and specificity were 0.74 (95 % CI: 0.67–0.79) and 0.73 (95 % CI: 0.70–0.77), respectively. The positive
likelihood ratio (PLR) and negative likelihood ratio (NLR) were 2.8 (95 % CI, 2.3–3.3) and 0.36 (95 % CI, 0.29–0.45),
respectively. In addition, the diagnostic odds ratio (DOR) was 8 (95 % CI, 5–11), and the overall area under the
SROC curve was 0.76 (95 % CI, 0.72–0.80).
Conclusions: Our study has demonstrated that MR-proADM is predictive of increased complications and higher
mortality rates in patients suffering from CAP. Future studies are warranted to determine the prognostic accuracy
of MR-proADM in conjunction with severity scores or other biomarkers and to determine an optimal cut-off level.
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Background
Lung infections are the most frequent type of infection
worldwide. Community-acquired pneumonia (CAP) is a
disease with a very wide range of possible outcomes. A
considerable proportion of patients can be treated as
outpatients. Additionally, CAP may serve as a sepsis pre-
cursor and is more likely to result in death in critically
ill patients [1]. Risk stratification is crucial to CAP pa-
tient management in the emergency department (ED) to
select the most appropriate care setting, including out-
patient treatment, admission to a hospital ward (HW) or
admission to an intensive care unit (ICU). Thus, clinical
studies are currently focusing on searching for the most
appropriate prognostic factors and risk stratification
tools in respiratory medicine.
Several risk scores (PSI, CURB65) have been developed
for assessing the severity of CAP and predicting mortality
[2, 3]. However, none are ideal for clinical use. Some
scores are too complicated to use in daily practice, and
some are not exempt from false-positive and false-
negative results. Blood biomarkers (for example, C-
reactive protein, procalcitonin, soluble triggering receptor
expressed on myeloid cells-1, and interleukin-1 beta) may
improve the diagnostic accuracy of those scores and may
provide additional information regarding the prognosis of
patients suffering from CAP [4–7].
Human adrenomedullin (ADM), a 52-amino acid pep-
tide, is a member of the calcitonin peptide family [8]. It
is widely expressed and intensively synthesized in organ-
isms suffering from severe infection. It is one of the
most potent vasodilating agents and functions in im-
mune modulation, antibiosis and metabolic regulation
[9–12]. ADM immediately binds to receptors near the
site of its production and has a short half-life [13]. The
more stable mid-regional (MR) fragment of the ADM
precursor is directly reflective of the level of the rapidly
degraded active ADM peptide [14]. Clinically, MR-
proADM is commonly used due to its better technical
viability than that of ADM. In addition, its level may be
indicative of the severity of infection. Increasing evi-
dence has shown that MR-proADM is a superior bio-
marker compared with others (such as procalcitonin and
soluble triggering receptor expressed on myeloid cells-1)
for prognostic purposes in sepsis [15, 16], as well as
CAP [17]. Thus, we performed this meta-analysis to sys-
tematically and quantitatively analyze all available publi-
cations that have assessed the prognostic accuracy of the
MR-proADM level in CAP patients to draw a firm con-
clusion from these studies.
Methods
Search strategy and selection criteria
Two investigators, Liu D and Xie LX, independently
performed the search and assessed the studies. Any
disagreement was resolved by consulting with a third
investigator (Xie LX). We searched PubMed, Embase,
Web of Knowledge and the Cochrane Library. The
search terms were as follows: (adrenomedullin or
ADM or proADM or "midregional proadrenomedul-
lin" or MR-proADM or proadrenomedullin) and ("re-
spiratory tract infection" or "respiratory infection" or
"pneumonia" or "community-acquired pneumonia" or
CAP). An example of the search details is presented
in Appendix 1. We included articles written in English
and Spanish, and no publication date restrictions were ap-
plied in the search.
Eligible studies had to have a well-defined reference
standard for patients diagnosed with CAP. They had to
collect data on MR-proADM levels in adult patients
(>18 years old) with mortality or complications from
CAP and provide sufficient data for construction of a
2 × 2 contingency table based on the results. Low risk
was defined by PSI score classes I to III and CURB-65
score class 1, and high risk was defined by PSI score
classes IV–V and CURB-65 score classes 2–5, according
to previous criteria [18, 19]. For studies providing mul-
tiple MR-proADM cut-off levels for prognostic accuracy,
the data presenting the maximum overall accuracy were
selected. All published studies had obtained ethics ap-
proval and consent for publication of these data. Ethics
approval was not sought as this systematic review which
synthesized the public data.
Data extraction and quality assessment
Two investigators, Liu D and Xie LX, independently ex-
tracted data and assessed the quality of the included
studies. Any conflicts were resolved by consulting with a
third investigator. The following data were extracted
from the original studies: the name of the first author,
publication year, country of origin, study design, clinical
setting, assay manufacturer, sample size, endpoints, per-
centage of high-risk patients according to the PSI score
or CURB-65 score, prevalence of mortality or complica-
tions, and MR-proADM cut-off level, and the true posi-
tive (TP), false positive (FP), false negative (FN), true
negative (TN), sensitivity (SEN) and specificity (SPE) of
the data. We contacted the corresponding authors if the
data were not presented or needed clarification. We
evaluated the quality of the included studies according
to the Quality Assessment of Diagnostic Accuracy Stud-
ies (QUADAS-2) checklist [20] for diagnostic studies.
Risk of bias was judged as “low”, “high” or “unclear”.
Statistical analysis
We chose the MIDAS module of STATA software, ver-
sion 12.0 (Stata Corporation, College Station, TX) and
Meta-Disc 1.4 (XI Cochrane Colloquium, Barcelona,
Spain) to perform statistical analyses. TP, FP, FN, and
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TN were tabulated based on the MR-proADM levels
and all-cause mortality in CAP. We used relative risk
(RR) to access the predictive value of MR-proADM
based on DerSimonian and Laird’s method [21]. The
Q-test and I2 index were conducted to assess inter-
study heterogeneity [22, 23]. A P value of less than
0.05 was considered statistically significant. Values of
25, 50 and 75 % for the I2 test represented low,
medium and high heterogeneity, respectively [24]. If
the I2 values were less than 50 %, then the fixed-
effects model was used; otherwise, the random-effects
model was used to analyze the data.
The presence of a threshold effect on the prognostic
accuracy of MR-proADM in CAP was evaluated with
the Spearman correlation coefficient between the logits
of sensitivity and specificity. If no threshold effect
existed, then a bivariate random-effects regression
model [25] was used to calculate the pooled sensitivity
(SEN), specificity (SPE), diagnostic odds ratio (DOR),
positive likelihood ratio (PLR), and negative likelihood
ratio (NLR). If a threshold effect existed, then we only
constructed a summary receiver operator characteristic
(SROC) curve by plotting the individual and summary
values of sensitivity and specificity to access overall
diagnostic accuracy [26].
Univariate meta-regression and subgroup analyses
were performed to examine the sources of potential het-
erogeneity in SEN and SPE. The covariates included the
following variables: Consecutive (if studies recruited
patients consecutively), Prevalence (prevalence of mor-
tality < 10 % or ≥ 10 %), Sample size (sample size < 500
or ≥ 500), and Blinded (if clinicians influenced patients’
outcomes without knowledge of the MR-proADM levels).
Results
Our database search resulted in the retrieval of 775 arti-
cles, of which 746 were eliminated for various reasons
related to the title and abstract, leaving 19 studies that
Fig. 1 Flow chart of the study selection process
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Table 1 Characteristics of included studies




















Albrich [27] 2011 Switzerland MRCT + CR ED 30 day mortality 925 - - 53.8 NA 5.41 1.5 36 295 14 580 72 66.3
Adverse events 14.5 0.75 256 475 11 183 95.9 27.8
Bello [28] 2012 Spain PR + CR ED 30 day mortality 224 61 73 (63–80) 59.2 61 5.8 1.066 12 68 1 143 92.3 67.46
Complications 64 0.833 98 26 48 52 67.35 66.23
Christ-Crain
[29]
2006 Switzerland PR + CR ED 6.9 ± 1.9 weeks 302 61.9 69.6 ± 17.0 - 60.2 12.6 1.8 30 74 8 190 80 72
Courtais [30] 2013 France PR + CR ED 30 day mortality 109 65.1 71.1 (53–84) - 56 8.26 1.8 7 25 2 75 77.8 75
Huang [31] 2009 America MPR ED 30 day mortality 1653 52 65.0 ± 18.5 - 39 6.4 1.3 72 418 34 1129 68 73
Kolditz [32] 2012 Germany PR + CR ED ICU admission
or 7 day mortality
51 49 72 (41–80) - - 17.6 1.05 6 6 3 36 67 85
Kruger [33] 2009 Germany RCT + CR ED 28 day mortality 728 59.1 59 ± 18.2 - - 2.5 0.959 14 168 4 542 77.8 76.3
Julian-Jimenez
[34]
2014 Spain PR + CR ED 30 day mortality 127 74 65.8 ± 20.02 55.9 55.1 10.3 1.85 11 21 2 93 84.6 81.4
Suberviola [35] 2012 Spain PR ICU In-hospital
mortality
49 67.3 59.4 ± 13.4 - - 35 4.86 9 5 8 27 53 84
Lacoma [36] 2014 Spain PR HW Complications 85 69.4 - 48.2 61.2 10.6 1.5 6 26 3 50 66.7 65.8
Bereciartua
Urbieta [37]
2011 Spain PR ED Unfavorable
outcome
250 31.6 71.1 - - 33.2 1.2 66 78 17 89 80 53
Renaud [38] 2012 America/
Spain/France
MRCT + CR ICU SCAP 877 58.8 73 (59–83) - - 5.6 1.8 49 184 31 613 61.3 76.9
SCAP severe community-acquired pneumonia, ICU intensive care unit, ED emergency department, HW hospital ward, PR prospective recruitment, CR consecutive recruitment, RR retrospective recruitment, RCT random-














were scrutinized by full-text reviews. Among these 19
studies, 1 study measured the level of ADM, 3 did not
provide sufficient information to construct a 2 × 2 table,
and 3 included ineligible patients (not CAP patients).
Ultimately, 12 studies [27–38] fulfilled our eligibility cri-
teria and were included (Fig. 1). The characteristics of
the included studies are listed in Table 1.
Characteristics of included studies
The included studies were published from 2006 to 2014.
Ten studies [27–33, 35, 36, 38] were published in English,
and two [34, 37] were in Spanish. All of the studies were
prospective cohorts, and three [27, 31, 38] were multiple-
center trials. Three of the studies [27, 33, 38] selected pa-
tients from a randomized clinical trial. All of the studies
were conducted in Europe. The mean patient ages varied
from 59 to 73 years, and the proportion of men ranged
from 31.6 to 74. The prevalence of mortality ranged from
2.5 to 35. The prevalence of complications ranged from
5.6 to 64. The studies were performed in EDs [27–34, 37],
ICUs [35, 38] and HWs [36]. The primary endpoint was
development of complications [27, 28, 36–38], and the
secondary endpoint was mortality [27–35]. In all of the
studies, MR-proADM was detected by an automated im-
munofluorescence assay (BRAHMS MR-proADM KRYP-
TOR, BRAHMS GmbH, Hennigsdorf, Germany) [39].
Study quality and publication bias
The quality of the included studies is shown in Appendix
2. Deek’s Funnel Plot is presented in Additional file
1: Figure S1.
Data synthesis and meta-analysis
Analysis of the association of MR-proADM with development
of complications
Five studies [27, 28, 36–38] with a total of 2361 pa-
tients were included in this group. However, a signifi-
cant threshold effect was observed (Spearman
correlation coefficient = 0.900; P = 0.037). Therefore,
we only calculated the overall area under the SROC
curve (AUC), which was 0.74 (95 % CI: 0.70–0.78)
(Additional file 2: Figure S2.).
Analysis of the effect of MR-proADM on mortality
Nine studies [27–39] with a total of 4119 patients were
included in this group. All of them showed that an
Fig. 2 Forest plot of association of MR-proADM to predict mortality in CAP. The overall pooled RR was 6.16 (95 % CI, 4.71–8.06)
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elevated MR-proADM level was associated with higher
risk of death from CAP. Because the heterogeneity be-
tween studies was 21.7 %, the fixed-effects model was
used. The pooled RR was 5.83 (95 % CI 4.53–7.52)
(Additional file 3: Figure S3.).
One study [35] analyzed CAP patients in an ICU with
a relatively high mortality rate. We found that this
study had a more heterogeneous population compared
with the other included studies. Thus, we excluded it
and focused on the association of the MR-proADM
level with short-term mortality in ED patients. Because
the heterogeneity between studies was 0.0 %, a fixed-
effects model was used to pool RR. For the ED patients,
an elevated MR-proADM level was associated with an
increased risk of short-term mortality (RR 6.16, 95 % CI
4.71–8.06) (Fig. 2).
We observed no statistically significant differences in
threshold effects (Spearman correlation coefficient =
0.252; P = 0.548). Thus, the bivariate random-effects re-
gression model was used to perform meta-analysis of
diagnostic test accuracy to evaluate the overall sensitivity
and specificity of MR-proADM for predicting mortality
in CAP. The pooled sensitivity and specificity were 0.74
(95 % CI: 0.67–0.79) and 0.73 (95 % CI: 0.70–0.77), re-
spectively (Fig. 3). The positive likelihood ratio (PLR)
and negative likelihood ratio (NLR) were 2.8 (95 % CI,
2.3–3.3) and 0.36 (95 % CI, 0.29–0.45), respectively. The
diagnostic odds ratio (DOR) was 8 (95 % CI, 5–11). The
overall area under the SROC curve was 0.76 (95 % CI,
0.72–0.80) (Fig. 4), indicating moderate diagnostic accur-
acy. The mean cut-off MR-proADM level for predicting
mortality in CAP was 1.416 ng/ml (IQR 0.959–1.85).
The overall I2 value for the bivariate model was 0.0 %
(95 % CI 0–100). The I2 values for the pooled SEN and
SPE were 0.00 % (95 % CI 0–100) and 81.31 % (95 % CI
69.13–93.48), respectively. Univariate meta-regression
and subgroup analyses were performed to examine the
sources of potential heterogeneity in SEN and SPE. The
covariates included the following: Consecutive (if
studies recruited patients consecutively), Prevalence
Fig. 3 Forest plot of the sensitivity and specificity of MR-proADM to predict mortality in CAP. The pooled sensitivity and specificity were 0.74
(95 % CI: 0.67–0.79) and 0.73 (95 % CI: 0.70–0.77), respectively
Liu et al. BMC Infectious Diseases  (2016) 16:232 Page 6 of 11
(prevalence < 10 % or ≥ 10 %), Sample size (sample
size < 500 or ≥ 500), and Blinded (if clinicians influ-
enced patients’ outcomes without knowledge of the
MR-proADM levels). The results showed that sample
size was significantly associated with the heterogeneity
of SEN, whereas the covariates Consecutive, Sample
size, Prevalence and Blinded were significantly associ-
ated with the heterogeneity of SPE (Fig. 5). We per-
formed subgroup analysis according to the different
prevalence rates of mortality. Three of the studies
[29, 32, 34] had a prevalence of over 10 %, with
pooled sensitivity and specificity values of 0.78 (95 %
CI: 0.67–0.89) and 0.78 (95 % CI: 0.72–0.84), respectively.
In addition, five of the studies [27, 28, 30, 31, 33] had a
prevalence of less than 10 %, with pooled sensitivity and
specificity values of 0.72 (95 % CI: 0.66–0.78) and 0.72
(95 % CI: 0.68–0.75), respectively.
Discussion
In this meta-analysis, we restricted our scope to patients
in the ED. We aimed to help clinicians to select the
most appropriate care setting for CAP patients in the
ED, including outpatient treatment, admission to a hos-
pital ward, or admission to an intensive care unit. We
first found that an elevated MR-proADM level was sig-
nificantly associated with an increased risk of mortality
in the ED patients with CAP. Clinical scores are recom-
mended for clinical decision-making in the evaluation of
CAP patients [40]. However, many studies have found
that these clinical scores are not exempt from false-
positive and false-negative results and are not ideal for
clinical use. Many patients are misclassified into the
high-risk classes IV and V according to the PSI score
[41]. Meta-analysis [42] has shown that the CURB-65
score has a sensitivity of only 0.62 for predicting mortal-
ity in CAP. Marrie et al. [43] have demonstrated that a
considerable number of CAP patients identified as high
risk based on a PSI level of IV or V can be treated safely
as outpatients, with subsequent low mortality. Our study
evaluated the prognostic value of ProADM in CAP and
revealed that the positive likelihood ratio (PLR) and
negative likelihood ratio (NLR) were 2.8 (95 % CI,
2.3–3.3) and 0.36 (95 % CI, 0.29–0.45), respectively.
These results indicate that MR-proADM is more clin-
ically useful than any of the risk scores previously
identified in another meta-analysis [42].
Because the included studies used different cut-off
values, simply pooling data from each trial may have
contributed to bias in the meta-analysis results. Thus, in
our meta-analysis, we conducted statistical analysis to
ensure the eligibility and reliability of our results before
tabulating the data from each trial. We used Meta-Disc
Fig. 4 Summary receiver operating characteristic (SROC) curve for the included studies. The numbers in the circle refer to the included studies;
Line = regression; the overall area under the SROC curve was 0.76 (95 % CI, 0.72–0.80)
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to evaluate the Spearman correlation coefficient. We cal-
culated the RR, SEN, SPE, DOR, PLR, and NLR for each
trial based on the premise that there were no significant
differences in the threshold effects (P > 0.05), indicating
that the heterogeneity attributed to the use of different
cut-off values was acceptable. Thus, our results are more
accurate than those of other diagnostic and prognostic
meta-analyses.
Our study has several limitations. First, all of the studies
included in our meta-analysis were conducted in Europe.
Thus, our results are restricted to Europeans. Second, Deek’s
funnel plot revealed the existence of potential publication
bias. Third, we could not determine the optimized cut-off
value because we failed to obtain the raw data from each
original article to construct an ROC curve. We attempted to
contact the corresponding authors to obtain the data, but it
was difficult to acquire the ProADM levels of the patients in
each trial. Albrich et al. [27] have examined the ProADM
level and CURB65 score combined and have found that the
risk of unfavorable outcome is low for patients with a
CURB65 score of 0–1 and a ProADM level of ≤0.75 nmol/l,
intermediate for patients with a CURB65 score of 2 and a
ProADM level of ≤1.5 nmol/l or a CURB class of 0–1 and a
ProADM level of between 0.75 and 1.5 nmol/L, and high
for all other patients. Another study [44] has also focused
on the prognosis of CAP patients using these ProADM cut-
off levels. All in all, further studies are warranted to define
the proper cut-off level for clinical use.
CAP is a complex pathophysiological process rather
than a specific syndrome. Thus far, no ideal biomarker or
clinical score has shown sufficient sensitivity and specifi-
city for clinical utility to predict death in CAP. Clinicians
need to comprehensively evaluate individual conditions.
Future research should highlight incorporation of MR-
Fig. 5 Univariate meta-regression and subgroup analyses (Sample size was significantly associated with the heterogeneity of SEN, whereas
Consecutive, Sample size, Prevalence and Blinded were significantly associated with the heterogeneity of SPE)
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proADM into an overall assessment of CAP prognosis in
combination with other clinical indexes instead of focus-
ing on adopting a biomarker-based or score-based ap-
proach to predicting mortality. Additionally, future studies
should be conducted specifically on patients with different
conditions (e.g., different CAP severities or different types
of infection) to help optimize therapeutic decisions for in-
dividual patients.
Conclusions
Our study has demonstrated that MR-proADM is pre-
dictive of increased complications and a higher mortality
rate in patients suffering from CAP. Further studies are
warranted to clarify the prognostic accuracy of MR-
proADM in conjunction with severity scores or other
biomarkers and to determine an optimal cut-off level.
Appendix 1
Example of search strategy for PubMed
(("adrenomedullin"[MeSH Terms] OR "adrenomedullin
"[All Fields]) OR ("Rev ADM"[Journal] OR "adm"[All
Fields] OR "Rev ADM"[Journal] OR "adm"[All Fields]
OR "ADM"[Journal] OR "adm"[All Fields] OR
"ADM"[Journal] OR "adm"[All Fields]) OR proADM[All
Fields] OR "midregional proadrenomedullin"[All Fields]
OR MR-proADM[All Fields] OR ("proadrenomedullin"
[Supplementary Concept] OR "proadrenomedullin"[All
Fields])) AND ("respiratory tract infection"[All Fields]
OR "respiratory infection"[All Fields] OR "pneumonia"[All
Fields] OR "community-acquired pneumonia"[All Fields]
OR CAP[All Fields])
Appendix 2
Table 2 QUADAS-2 results of included studies
Study Risk of bias Applicability concerns
Patient selection Index test Reference standard Flow and timing Patient selection Index test Reference standard
Albrich [27] L L L L L L L
Bello [28] L L L L L L L
Christ-Crain [29] L L L L L L L
Courtais [30] L L L L L L L
Huang [31] H L L L H L L
Kolditz [32] L L L L L L L
Kruger [33] L L L L L L L
Julian-Jimenez [34] L L L L L L L
Suberviola [35] H L L L H L L
Lacoma [36] H L L L H L L
Bereciartua Urbieta [37] H L L L H L L
Renaud [38] L L L L L L L
L low risk, H high risk, U unclear risk
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Additional files
Additional file 1: Figure S1. Deek’s funnel plot. Deek’s funnel plot
asymmetry test for publication bias (A. for development of complications;
B. for prediction of mortality). (TIF 755 kb)
Additional file 2: Figure S2. SROC curve of the included studies. The
numbers in the circle refer to the included studies; Line = regression; the
overall area under the SROC curve was 0.74 (95 % CI: 0.70–0.78). (TIF 241 kb)
Additional file 3: Figure S3. An elevated MR-proADM level was associ-
ated with a higher risk of death in CAP. The pooled RR was 5.83 (95 % CI
4.53–7.52). (TIF 215 kb)
Abbreviations
CAP, community-acquired pneumonia; CI, confidence interval; CR, consecu-
tively recruitment; DOR, diagnostic odds ratio; ED, emergency department;
FN, false negative; FP, false positive; LR, likelihood ratio; MPR, multiple-centre
prospectively recruitment; MRCT, multiple-centre random control trail;
MR-proADM, midregional proadrenomedullin; NLR, negative likelihood ra-
tio; PLR, positive likelihood ratio; PR, prospectively recruitment; QUADAS,
quality assessment of diagnostic accuracy studies; RCT, random control
trail; RR, risk ratio; SEN, sensitivity; SPE, specificity; SROC, summary re-
ceiver operator characteristic; TN, true negative; TP, true positive.
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